RYTMMEDIUM SIGNALFINANCIAL10-K

RYTM showed meaningful improvement in operating performance with reduced losses while maintaining revenue growth momentum, as evidenced by cumulative product sales growing substantially from $227.6 million to $422.5 million.

The company demonstrated notable progress toward profitability with operating losses narrowing by 28% and net losses improving by 25%, suggesting better operational efficiency. However, the significant cash position decline from $89.1M to $54.3M raises questions about funding runway, though this may reflect strategic deployment of capital given the substantial revenue growth trajectory.

Comparing 2026-02-26 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

RYTM's financial profile improved meaningfully with operating and net losses both narrowing by approximately 25-28% while maintaining growth investments. The balance sheet shows signs of business expansion with accounts receivable and inventory both growing around 40%, indicating increased commercial activity. However, the 39% decline in cash position to $54.3M warrants monitoring, though total assets still grew 22% as R&D expenses were reduced by 30% while SG&A expenses increased 35%, suggesting a shift toward commercialization activities.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+40.9%
$18.5M→$26.1M

Receivables surged 40.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Cash & Equivalents
Balance Sheet
-39.1%
$89.1M→$54.3M

Cash declined 39.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Inventory
Balance Sheet
+37.4%
$18.7M→$25.8M

Inventory surged 37.4% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

SG&A Expense
P&L
+35.1%
$144.3M→$194.9M

SG&A up 35.1% — significant increase in sales or administrative costs, monitor impact on operating leverage.

R&D Expense
P&L
-29.7%
$238.0M→$167.3M

R&D spending cut 29.7% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+27.7%
-$265.5M→-$192.0M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Current Assets
Balance Sheet
+24.8%
$374.2M→$466.9M

Current assets grew 24.8% — improving short-term liquidity or inventory/receivables build.

Net Income
P&L
+24.6%
-$260.6M→-$196.5M

Net income grew 24.6% — bottom-line growth signals improving overall business health.

Total Assets
Balance Sheet
+22.4%
$392.3M→$480.2M

Asset base grew 22.4% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-28
ADDED
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $ 3.8 billion, based on the closing price of the registrant s Common Stock on June 30, 2025, the last business day of the registrant s most recently completed second fiscal quarter.
There were 68,285,039 shares of the registrant's Common Stock outstanding as of February 24, 2026.
SUMMARY RISK FACTORS Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A.
To date, we have generated approximately $422.5 million from product sales.
We have incurred significant operating losses 3 Table of Conten ts since our inception, anticipate that we will incur continued losses for the foreseeable future and may never achieve profitability.
Moreover, our ability to recruit patients to our trials may be materially adversely affected.
Even if we complete the necessary clinical trials, the regulatory and marketing approval process is expensive, time consuming and uncertain and may prevent us from obtaining additional approvals for the commercialization of setmelanotide.
We also are developing two earlier-stage investigational MC4R agonists, bivamelagon (formerly LB54640), an oral small molecule, and RM-718, designed for weekly subcutaneous administration.
These investigational assets, for which we possess global rights, are specifically designed to exhibit high selectivity for MC4R while functionally sparing MC1R.
As a result, they are not expected to induce hyperpigmentation.
REMOVED
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $ 2.4 billion, based on the closing price of the registrant s Common Stock on June 28, 2024, the last business day of the registrant s most recently completed second fiscal quarter.
There were 63,223,727 shares of the registrant's Common Stock outstanding as of February 24, 2025.
Our actual results may differ significantly from the results discussed in the forward-looking statements.
To date, we have generated approximately $227.6 million from product sales.
We have incurred significant operating losses since our inception, anticipate that we will incur continued losses for the foreseeable future and may never achieve profitability.
Moreover, our ability to recruit patients to our trials may be materially adversely affected .
Our late-stage clinical development program in acquired hypothalamic obesity presents a meaningful expansion opportunity for setmelanotide.
Acquired hypothalamic obesity is a rapid-onset, severe obesity caused by injury to the hypothalamus, which may impair MC4R pathway signaling.
With setmelanotide, we observed positive efficacy results in our Phase 2 trial, with a clinically meaningful BMI reduction of 25.5% in 11 patients who reached 12 months or more on therapy through the extension phase of the trial.
In addition, similar positive data suggesting potential efficacy have been reported from a pre-approval, early-access program in France.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →